NKTR peer analysis
Nektar (NKTR) against its competitors: price, today's move, 1-year return and market value side by side.
NKTR and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ANL Adlai Nortye | $9.55 | -7.10% | 587.10% | – |
| CGEN Compugen | $1.98 | -2.94% | 20.00% | $187.56M |
| CHRS Coherus Oncology | $0.83 | -7.60% | -51.17% | $128.25M |
| CRVS Corvus Pharmaceuticals | $10.03 | -1.96% | 29.25% | $843.73M |
| IMCR Immunocore | $29.79 | -2.30% | -7.46% | – |
| IMTX Immatics | $7.20 | -1.50% | -30.90% | – |
| IPHA Innate Pharma | $1.46 | -1.35% | -33.64% | $163.08M |
| MGNX MacroGenics | $2.40 | 0.84% | 50.47% | $152.88M |
| RCUS Arcus Biosciences | $17.84 | -1.90% | -11.61% | $2.32B |
| XNCR Xencor | $29.68 | -0.47% | 110.05% | $2.22B |
| NKTR Nektar | $36.90 | -5.07% | -41.24% | $1.33B |
- NKTR's peers: ANL (Adlai Nortye), CGEN (Compugen), CHRS (Coherus Oncology), CRVS (Corvus Pharmaceuticals), IMCR (Immunocore), IMTX (Immatics), IPHA (Innate Pharma), MGNX (MacroGenics).
Updated 2026-11-03 02:02 UTC